MedTech-related health technology assessments from NIHR in October 2022

The National Institute for Health and Care Research (NIHR) funds valuable independent research for health and social care decision-makers in England. Reports from the Health Technology Assessment (HTA) Programme are published in the NIHR HTA Journal and inform NICE guidance.

In October 2022, one MedTech-related assessment for photodynamic versus white-light-guided resection of first-diagnosis non-muscle-invasive bladder cancer was published in the NIHR HTA Journal. It was based on a multicenter, pragmatic, open-label, parallel-group, non-masked, superiority randomized controlled trial (PHOTO RCT), which enrolled 538 participants from 22 UK hospitals.

It was concluded that photodynamic diagnosis-guided transurethral resection of bladder tumor did not reduce recurrences, nor was it likely to be cost-effective compared with white light at three years. Photodynamic diagnosis-guided transurethral resection of bladder tumor is not supported in the management of primary intermediate- to high-risk non-muscle-invasive bladder cancer. Further work should include the modeling of appropriate surveillance schedules and exploring predictive and prognostic biomarkers.

See the full details here.

This news is just one of about 300 market access news collected by our team in the subscription services "HTA Alerts" and "Reimbursement Alerts" every two weeks from more than 80 organizations. Access our paid subscription services to stay on top of all developments specifically for your products in Europe (reimbursement news) and globally (HTA news). First EU issues of both newsletters are available for download free-of-charge.

Not ready for a subscription service? Subscribe to our free-of-charge newsletter delivered every second week to get updates about key reimbursement developments in Europe (10-12 news every two weeks).